Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Issues related to FY2026 Appropriations
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Source: Senate LDA
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
ORPHAN Cures Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
EPIC Act of 2025
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Treat and Reduce Obesity Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Issues related to FY2026 Appropriations
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2026 Appropriations
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
Issues related to FY2026 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Issues related to FY2026 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act
Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act
Issues related to FY2024 Appropriations
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to FY2024 Appropriations
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to FY2024 Appropriations
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to FY2024 Appropriations
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to FY2024 Appropriations
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act
Issues related to FY2024 Appropriations
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Prescription drug manufacturing and supply chains
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars Issues related to the 340B program Issues related to tax
Issues related to FY 2022 Appropriations S. 2599, H.R. 4356 and H.R. 4502 Agriculture, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Prescription drug manufacturing and supply chains
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars Issues related to the 340B program Issues related to tax
Issues related to FY 2022 Appropriations
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars Issues related to the 340B program Issues related to tax
Prescription drug manufacturing and supply chains
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars
Issues related to FY 2022 Appropriations
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Issues related to FY2026 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2026 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2026 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2026 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2024 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2024 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY2024 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Issues related to FY 2022 Appropriations
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D redesign, rebate reform and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars H.R. 13919 (Issues related to COVID-19 relief and the Medicaid rebate cap)
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE